Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on June 14, 2022. The filing reports a corporate governance event: the election of a new member to the Board of Directors.
Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the appointment of a director and associated compensation.
Material Changes
The Board of Directors increased its size to eleven members effective June 14, 2022, following the election of Dr. Deepak L. Bhatt. No material changes to financial operations or strategy are reported in this document.
Management Commentary and Compensation
Dr. Deepak L. Bhatt, M.D., M.P.H., was elected to the Board and will serve on the Science and Technology Committee. The Board determined he is independent under NYSE Listing Standards. His compensation includes:
- An annual retainer of $105,000.
- An annual award of deferred share units valued at $200,000 on the date of grant.
There are no related party transactions or special arrangements between the Company and Dr. Bhatt.
Key Facts for Investors
- Dr. Deepak L. Bhatt joined the Board of Directors on June 14, 2022.
- The Board size increased to eleven members.
- Dr. Bhatt brings over 20 years of experience in cardiology and clinical trials.
- His total annual compensation package is valued at $305,000 (retainer plus deferred share units).
- No financial results or guidance are provided in this specific filing.